Arch Biopartners
Company Details
Status: Public
Employees: 11-50
Location:
Toronto, Canada
Type:
sample
Technology:
sample
sample
sample
sample
About: Arch works closely with the scientific community, universities and research institutions to advance and build the value of select medical innovations, develop the most promising intellectual property, and create value for its investors.
The company holds a strong patent portfolio of new drug candidates to prevent inflammation and organ injury.
Arch’s Phase I and Phase II clinical trials led to LSALT peptide (Metablok), being the first novel therapeutic to join the Canadian Treatments for COVID-19 trial, a multi-centre adaptive, randomized, open-label, controlled clinical trial involving fifty-five hospitals across Canada.
• Arch scientists described a novel mechanism of action for organ inflammation in the journal Cell.
• Arch scientists identified the enzyme dipeptidase-1 (DPEP1) as a major neutrophil (white blood cell) adhesion receptor in the lungs, kidneys and liver.
• DPEP1 was shown to be the target of LSALT peptide (Metablok), the Company’s lead drug candidate targeting inflammation in the lungs and kidneys.
Arch is currently working to advance LSALT peptide through the production of additional human safety and efficacy data in a Phase II trial to prevent IRI-acute kidney injury (AKI).
Please follow the company on LinkedIn, and subscribe at the website for the latest science and investor news.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Arch Biopartners | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.